Claimed effect · Triptorelin

Does Triptorelin help with testosterone suppression in advanced prostate cancer?

A
Grade A — established in humansApproval programme; decades of use · effect size: large
Short answerEstablished in humans. Approval programme; decades of use point the same way: a large effect. The licensed indication. Continuous GnRH receptor occupancy desensitises the pituitary, and after a transient surge testosterone falls to castrate levels. The Trelstar label carries three depot intervals for this use and the effect is the basis of forty years of androgen-deprivation therapy.

What the studies show

The licensed indication. Continuous GnRH receptor occupancy desensitises the pituitary, and after a transient surge testosterone falls to castrate levels. The Trelstar label carries three depot intervals for this use and the effect is the basis of forty years of androgen-deprivation therapy.

Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.

  1. 1
    Trelstar (triptorelin pamoate) prescribing information.DailyMed, read 29 Oct 2026Advanced prostate cancer; three depot intervals; pharmacokinetics and the decapeptide structure.

In context

Triptorelin is a synthetic ten-amino-acid analogue of gonadotropin-releasing hormone, approved since the 1980s and sold as Trelstar for advanced prostate cancer and Triptodur for central precocious puberty. Given continuously it shuts the reproductive axis down after an initial surge. Its grey-market reputation is the opposite use — a single low dose to restart testosterone production after anabolic steroids — and that rests on one published case report of one man, not on any trial.

Triptorelin is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Triptorelin proven to help with testosterone suppression in advanced prostate cancer?
Yes, as far as human trials can show it: Approval programme; decades of use. LYO grades this outcome A.
What studies are behind the grade?
The licensed indication. Continuous GnRH receptor occupancy desensitises the pituitary, and after a transient surge testosterone falls to castrate levels. The Trelstar label carries three depot intervals for this use and the effect is the basis of forty years of androgen-deprivation therapy.
Is Triptorelin approved for this?
Triptorelin is an approved medicine (Approved (Rx)); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Triptorelin

Written and maintained by LYO Research — how pages are written and checked. Reviewed 29 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →